ALG.APV-527

Aptevo Therapeutics has announced progress on APVO711, a dual-mechanism bispecific antibody that simultaneously blocks PD-L1 and activates CD40, potentially overcoming resistance to standard checkpoint inhibitors.

Aptevo Therapeutics has closed a $2.1 million financing through a registered direct offering and concurrent private placement priced at $1.19 per share.

Phase 1 dose escalation study of ALG.APV-527 demonstrates disease stabilization in 59% of evaluable patients across multiple solid tumor types, with notable durability in breast, colon, and prostate cancers.

Aptevo Therapeutics and Alligator Bioscience's ALG.APV-527 met key Phase 1 trial endpoints for safety, tolerability, and biological activity in solid tumors.